TRANSTHERA-B (02617) Included in Hang Seng Composite Index, Expected to Become Hong Kong Stock Connect Eligible Stock

Stock News

Aug 22

On August 22nd, Hang Seng Indexes Company announced the quarterly review results of the Hang Seng Index Series as of June 30, 2025. TRANSTHERA-B (02617) was included in the Hang Seng Composite Index, with changes to be implemented after market close on Friday, September 5th and taking effect from Monday, September 8th. The Shanghai and Shenzhen Stock Exchanges will accordingly adjust the scope of investable stocks under the Hong Kong Stock Connect program.

According to a research report by Huatai Securities, TRANSTHERA-B is likely to be included in the Hong Kong Stock Connect program as it meets a series of criteria including market capitalization, liquidity, and listing duration.

TRANSTHERA announced that its independently developed multi-target kinase inhibitor TT-00420 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant prostate cancer. The company stated that TT-00420 is currently a multi-target kinase inhibitor in global Phase III registration trials, which targets FGFR/VEGFR, JAK, and Aurora kinases to exert anti-tumor effects. Clinical trials currently underway in the United States and China show that it has therapeutic potential in the treatment of various solid tumors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1103128195"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1103128195\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1103128195?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-22 20:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103128195","market":"sg","top_or_hot":-1,"title":"TRANSTHERA-B (02617) Included in Hang Seng Composite Index, Expected to Become Hong Kong Stock Connect Eligible Stock","media":"Stock News","content":"<p>On August 22nd, Hang Seng Indexes Company announced the quarterly review results of the Hang Seng Index Series as of June 30, 2025. TRANSTHERA-B (02617) was included in the Hang Seng Composite Index, with changes to be implemented after market close on Friday, September 5th and taking effect from Monday, September 8th. The Shanghai and Shenzhen Stock Exchanges will accordingly adjust the scope of investable stocks under the Hong Kong Stock Connect program.</p>\n<p>According to a research report by Huatai Securities, TRANSTHERA-B is likely to be included in the Hong Kong Stock Connect program as it meets a series of criteria including market capitalization, liquidity, and listing duration.</p>\n<p>TRANSTHERA announced that its independently developed multi-target kinase inhibitor TT-00420 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant prostate cancer. The company stated that TT-00420 is currently a multi-target kinase inhibitor in global Phase III registration trials, which targets FGFR/VEGFR, JAK, and Aurora kinases to exert anti-tumor effects. Clinical trials currently underway in the United States and China show that it has therapeutic potential in the treatment of various solid tumors.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TRANSTHERA-B (02617) Included in Hang Seng Composite Index, Expected to Become Hong Kong Stock Connect Eligible Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTRANSTHERA-B (02617) Included in Hang Seng Composite Index, Expected to Become Hong Kong Stock Connect Eligible Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-22 20:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On August 22nd, Hang Seng Indexes Company announced the quarterly review results of the Hang Seng Index Series as of June 30, 2025. TRANSTHERA-B (02617) was included in the Hang Seng Composite Index, with changes to be implemented after market close on Friday, September 5th and taking effect from Monday, September 8th. The Shanghai and Shenzhen Stock Exchanges will accordingly adjust the scope of investable stocks under the Hong Kong Stock Connect program.</p>\n<p>According to a research report by Huatai Securities, TRANSTHERA-B is likely to be included in the Hong Kong Stock Connect program as it meets a series of criteria including market capitalization, liquidity, and listing duration.</p>\n<p>TRANSTHERA announced that its independently developed multi-target kinase inhibitor TT-00420 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant prostate cancer. The company stated that TT-00420 is currently a multi-target kinase inhibitor in global Phase III registration trials, which targets FGFR/VEGFR, JAK, and Aurora kinases to exert anti-tumor effects. Clinical trials currently underway in the United States and China show that it has therapeutic potential in the treatment of various solid tumors.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02617","symbol_name":"药捷安康-B","start_time":0,"source_url":"","article_id":"1103128195","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103128195","pubTimestamp":1755866914,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"On August 22nd, Hang Seng Indexes Company announced the quarterly review results of the Hang Seng Index Series as of June 30, 2025. TRANSTHERA-B (02617) was included in the Hang Seng Composite Index,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02617":"药捷安康-B","BK1161":"生物科技","HSCEI":"国企指数","07226":"南方两倍做多恒科","HSTECH":"恒生科技指数","HSCI":"恒生综合指数","YANG":"三倍做空富时中国ETF-Direxion","BK4614":"Manus概念股"},"translate_title":"Tranthera-B(02617)纳入恒生综合指数有望成为港股通合资格股票","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":1,"07226":1,"HSCEI":1,"HSCI":1,"HSTECH":1,"YANG":1},"content_text":"On August 22nd, Hang Seng Indexes Company announced the quarterly review results of the Hang Seng Index Series as of June 30, 2025. TRANSTHERA-B (02617) was included in the Hang Seng Composite Index, with changes to be implemented after market close on Friday, September 5th and taking effect from Monday, September 8th. The Shanghai and Shenzhen Stock Exchanges will accordingly adjust the scope of investable stocks under the Hong Kong Stock Connect program.\nAccording to a research report by Huatai Securities, TRANSTHERA-B is likely to be included in the Hong Kong Stock Connect program as it meets a series of criteria including market capitalization, liquidity, and listing duration.\nTRANSTHERA announced that its independently developed multi-target kinase inhibitor TT-00420 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant prostate cancer. The company stated that TT-00420 is currently a multi-target kinase inhibitor in global Phase III registration trials, which targets FGFR/VEGFR, JAK, and Aurora kinases to exert anti-tumor effects. Clinical trials currently underway in the United States and China show that it has therapeutic potential in the treatment of various solid tumors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}